ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere

• Status: Unknown status
• Trial end date: 2005-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purposes of this study are to determine if DN-101 plus Taxotere lowers PSA levels, delays or limits disease progression and is safe with minimal side effects.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novacea
• Collaborator: Aventis Pharmaceuticals
• Treatments: Androgens; Calcitriol; Docetaxel

Criteria

• Three rising PSA measurements OR a new metastatic lesion

• Adequate liver and kidney function

• Ongoing hormonal therapy

• No hospitalization for angina, heart attack or congestive heart failure within the last 12 months

• No kidney stones in the last 5 years